TKTakafumi Kuzuya

Takafumi Kuzuya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takafumi Kuzuya has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of Interleukin-2 mRNA in Whole Blood as a Parameter for Monitoring Cyclosporine Pharmacodynamics

    by Takafumi Kuzuya, Takaaki Kobayashi, Akio Katayama, Takaharu Nagasaka, Yuko Miwa, Kazuharu Uchida, Akimasa Nakao, Kiyofumi Yamada

    Inhibition of cytokine production is the main immunosuppressive effect of cyclosporine (CsA), which is widely used in organ transplantation. Pharmacodynamic (PD) assay for evaluating the inhibition of interleukin-2 (IL-2) production for each patient could provide a more appropriate dosing regimen. We measured the suppression of IL-2 mRNA expression in whole blood following the addition of a range of CsA concentrations by a real-time reverse transcription-polymerase chain reaction (RT-PCR) method. Individual CsA sensitivity on the IL-2 mRNA expression was assessed with healthy subjects both in vitro and ex vivo. We also evaluated it in pre-transplant patients before taking immunosuppressive drugs. Sigmoid Emax model was used to analyze the relationship between CsA concentration and IL-2 mRNA expression. The assay was completed within 8 h. The concentration that resulted in IC50 showed high reproducibility and specificity among the healthy subjects (pn=5). Ex vivo study indicated similar inhibition profiles to those of in vitro studies (n=3). The values of IC50 obtained from patients (n=22) also showed large variations and were significantly lower than those from healthy subjects (p<0.05). Semi-quantitative RT-PCR was considered to be a rapid and reliable assay. Our data imply that measurement of IL-2 mRNA levels in whole blood could be valuable in monitoring CsA PD in transplant patients.


  • Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1

    by Takafumi Kuzuya, Takaaki Kobayashi, Natsuko Moriyama, Takaharu Nagasaka, Itsuo Yokoyama, Kazuharu Uchida, Akimasa Nakao, Toshitaka Nabeshima

    Cyclosporine A (CsA) is a critical immunosuppressive drug with a narrow therapeutic range and wide interindividual variation in its pharmacokinetics. Many factors, including P-glycoprotein (PGP), influence the oral bioavailability and interpatient variability of CsA. A number of polymorphisms have been identified in the human MDR1 gene, and some of them have been found to be associated with an altered expression of PGP. We have investigated the role of these polymorphisms in CsA absorption from kidney transplant recipients. In addition, we also investigated the effect of amlodipine on CsA absorption. The area under the time-concentration curve from 0 to 2 hr (AUC0–2) estimated by the trapezoidal rule was used for the evaluation of extent of CsA absorption. The genotypes were identified by a polymerase chain reaction, restriction fragment length polymorphism analysis. No association was found between polymorphisms in the MDR1 and CsA AUC0–2/dose/kg. In contrast, the combination of amlodipine significantly increased CsA AUC0–2/dose/kg (706.2 μg·hr/L to 819.2 μg·hr/L, P <0.05). Furthermore, we attempted to compare MDR1 polymorphisms and the absorption of CsA again without patients receiving amlodipine, but there was still no significant difference. There is no relationship between polymorphisms for MDR1 and CsA absorption, suggesting polymorphisms for MDR1 cannot account for the interpatient variability of CsA. Amlodipine, which is the substrate of PGP, significantly increased CsA absorption. These results indicate that PGP plays a significant role in CsA absorption, but its polymorphisms could not influence the CsA absorption.


  • Interference of Hematocrit in the Tacrolimus II Microparticle Enzyme Immunoassay

    by Takafumi Kuzuya, Yozo Ogura, Yoko Motegi, Natsuko Moriyama, Toshitaka Nabeshima

    The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 μg/L and 15 μg/L. Both coefficients of variation were over 20% (21% at 7.5 μg/L of tacrolimus and 22% at 15 μg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47;P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.54;P < 0.0001 at 15 μg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93;P < 0.0001 at 7.5 μg/L tacrolimus, r2 = 0.91;P < 0.0001 at 15 μg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.


  • Open Access

    Clinical evaluations of a newly developed seralyzer reagent strip system for theophylline determination in body fluid.

    by Takafumi Kuzuya, Yozo Ogura, Masaya Hasegawa, Toshiaki Nakamura, Keiko Nakano, Ikuo Johno, Shikifumi Kitazawa